Premium Brands Holdings Corp Earnings Call Insights for 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy PBH?
Source: Yahoo Finance
- Strong Sales Capacity: Premium Brands Holdings Corp boasts a sales capacity of approximately $1.5 billion, establishing a solid foundation for future growth and positioning the company to capture a larger market share in a competitive landscape.
- Controlled Project Budgets: The company has successfully managed to keep its project CapEx between $70 million and $80 million annually, a strategy that will help avoid the high expenditures of the past four years, thereby enhancing financial flexibility.
- Organic Growth Momentum: Premium Brands is experiencing strong organic growth in the Canadian market, particularly in the discount channel, which has exceeded expectations and will further enhance its competitive position and brand influence.
- Cost Pressure Challenges: Despite the company's dynamic pricing strategies, it continues to face cost pressures from inflation in core commodities like beef and chicken, which may impact short-term profitability and sales growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PBH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PBH
Wall Street analysts forecast PBH stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 54.590
Low
66.00
Averages
76.00
High
86.00
Current: 54.590
Low
66.00
Averages
76.00
High
86.00
About PBH
Prestige Consumer Healthcare Inc. is a consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Premium Brands Holdings Corp Earnings Call Insights for 2026
- Strong Sales Capacity: Premium Brands Holdings Corp boasts a sales capacity of approximately $1.5 billion, establishing a solid foundation for future growth and positioning the company to capture a larger market share in a competitive landscape.
- Controlled Project Budgets: The company has successfully managed to keep its project CapEx between $70 million and $80 million annually, a strategy that will help avoid the high expenditures of the past four years, thereby enhancing financial flexibility.
- Organic Growth Momentum: Premium Brands is experiencing strong organic growth in the Canadian market, particularly in the discount channel, which has exceeded expectations and will further enhance its competitive position and brand influence.
- Cost Pressure Challenges: Despite the company's dynamic pricing strategies, it continues to face cost pressures from inflation in core commodities like beef and chicken, which may impact short-term profitability and sales growth.
See More
Prestige Consumer Healthcare Announces Q4 Earnings Release Date
- Earnings Release Schedule: Prestige Consumer Healthcare will issue its fiscal 2026 fourth quarter and year-end earnings on May 13, 2026, after market close, which is expected to significantly impact investor sentiment.
- Conference Call Timing: The company will host a conference call on May 14 at 8:30 a.m. ET to discuss the earnings results, aiming to enhance transparency and strengthen investor relations.
- Participation Method: Investors can access the live webcast via the company's Investor Relations page, with a recommendation to join 10 minutes early, reflecting the company's commitment to a positive investor experience.
- Replay Availability: A replay of the conference call will be available for approximately one week post-event on the Investor Relations page, ensuring that investors who could not attend live can still access critical information.
See More
Investment Choices in Uncertain Markets
- Stable Dividend Returns: Weis Markets declared a quarterly dividend of $0.34 per share in February 2026, yielding approximately 2% annually, attracting value investors in uncertain markets due to its consistent cash flow.
- Competitive Market Advantage: Ingles Markets operates hundreds of supermarkets in the Southeast and owns its own dairy processing facility; despite facing activist shareholder challenges, its vertical integration may unlock value for the company.
- Strategic Acquisition Plan: Prestige Consumer Healthcare signed a definitive agreement to acquire the Breathe Right brand for $1.045 billion, expected to become its largest brand and enhance its competitive edge in the healthcare market.
- Market Volatility Response: In the current uncertain market, Weis, Ingles, and Prestige exemplify durability, cash flow, and relevance during economic downturns, prompting investors to cautiously observe and gradually build positions.
See More
Steady Investments in Uncertain Markets
- Stable Dividend Yield: Weis Markets declared a quarterly dividend of $0.34 per share in February 2026, yielding approximately 2% annually, attracting investors seeking safe investments in uncertain market conditions.
- Value Investment Opportunity: Weis shares trade at a P/E ratio of about 15.6, below the consumer retail industry average of 19.2, and the recent drop below the 200-day moving average signals potential buying interest from value-oriented investors.
- Acquisition Driving Growth: Prestige Consumer Healthcare signed a definitive agreement to acquire the Breathe Right brand for $1.045 billion, expected to become its largest brand and enhance the company's international presence in the health care market, likely boosting future revenue.
- Shareholder Activism Catalyst: Ingles Markets is facing a challenge from investment firm Summer Road LLC, which could act as a catalyst for unlocking value, although investors should proceed cautiously and consider gradual accumulation to mitigate potential risks.
See More
Health Care Stocks Decline Late Friday
- Overall Decline: Late Friday, the NYSE Health Care Index experienced a downturn, indicating increasing market concerns about the healthcare sector, which may negatively impact investor confidence.
- Market Reaction: The decline in healthcare stocks may be linked to overall economic uncertainty, as investors anticipate potential policy changes that could lead to capital outflows from the sector, thereby affecting stock performance.
- Industry Impact: The weak performance of the healthcare sector could hinder related companies' financing capabilities and market valuations, especially under the current economic conditions where operational pressures are heightened.
- Investor Strategy Adjustment: As healthcare stocks decline, investors may reassess their portfolios, considering reallocating funds to other sectors with greater growth potential to mitigate risks associated with market volatility.
See More
Prestige Consumer to Acquire Breathe Right Brand for $1.045 Billion
- Acquisition Overview: Prestige Consumer Healthcare is set to acquire the Breathe Right brand and other OTC health products from Foundation Consumer Brands for $1.045 billion in cash, with the deal expected to close in the first half of fiscal 2027, indicating a proactive strategy in expanding its product portfolio.
- Financial Highlights: The acquired portfolio includes Dimetapp and Anbesol, generating $200 million in annual revenue and $95 million in EBITDA, suggesting that this acquisition will significantly enhance Prestige's financial foundation and competitive position in the market.
- Financing Strategy: Prestige plans to finance the acquisition using cash on hand and a new term loan, demonstrating flexibility in capital management and confidence in future growth, although it may impact short-term liquidity.
- Market Reaction: Following the acquisition announcement, Prestige Consumer Healthcare's stock rose 1.6% in premarket trading, reflecting investor optimism about the deal and its potential to drive further growth in the OTC market.
See More
Premium Brands Holdings Corp Earnings Call Insights for 2026
- Strong Sales Capacity: Premium Brands Holdings Corp boasts a sales capacity of approximately $1.5 billion, establishing a solid foundation for future growth and positioning the company to capture a larger market share in a competitive landscape.
- Controlled Project Budgets: The company has successfully managed to keep its project CapEx between $70 million and $80 million annually, a strategy that will help avoid the high expenditures of the past four years, thereby enhancing financial flexibility.
- Organic Growth Momentum: Premium Brands is experiencing strong organic growth in the Canadian market, particularly in the discount channel, which has exceeded expectations and will further enhance its competitive position and brand influence.
- Cost Pressure Challenges: Despite the company's dynamic pricing strategies, it continues to face cost pressures from inflation in core commodities like beef and chicken, which may impact short-term profitability and sales growth.
See More
Prestige Consumer Healthcare Announces Q4 Earnings Release Date
- Earnings Release Schedule: Prestige Consumer Healthcare will issue its fiscal 2026 fourth quarter and year-end earnings on May 13, 2026, after market close, which is expected to significantly impact investor sentiment.
- Conference Call Timing: The company will host a conference call on May 14 at 8:30 a.m. ET to discuss the earnings results, aiming to enhance transparency and strengthen investor relations.
- Participation Method: Investors can access the live webcast via the company's Investor Relations page, with a recommendation to join 10 minutes early, reflecting the company's commitment to a positive investor experience.
- Replay Availability: A replay of the conference call will be available for approximately one week post-event on the Investor Relations page, ensuring that investors who could not attend live can still access critical information.
See More
Investment Choices in Uncertain Markets
- Stable Dividend Returns: Weis Markets declared a quarterly dividend of $0.34 per share in February 2026, yielding approximately 2% annually, attracting value investors in uncertain markets due to its consistent cash flow.
- Competitive Market Advantage: Ingles Markets operates hundreds of supermarkets in the Southeast and owns its own dairy processing facility; despite facing activist shareholder challenges, its vertical integration may unlock value for the company.
- Strategic Acquisition Plan: Prestige Consumer Healthcare signed a definitive agreement to acquire the Breathe Right brand for $1.045 billion, expected to become its largest brand and enhance its competitive edge in the healthcare market.
- Market Volatility Response: In the current uncertain market, Weis, Ingles, and Prestige exemplify durability, cash flow, and relevance during economic downturns, prompting investors to cautiously observe and gradually build positions.
See More
Steady Investments in Uncertain Markets
- Stable Dividend Yield: Weis Markets declared a quarterly dividend of $0.34 per share in February 2026, yielding approximately 2% annually, attracting investors seeking safe investments in uncertain market conditions.
- Value Investment Opportunity: Weis shares trade at a P/E ratio of about 15.6, below the consumer retail industry average of 19.2, and the recent drop below the 200-day moving average signals potential buying interest from value-oriented investors.
- Acquisition Driving Growth: Prestige Consumer Healthcare signed a definitive agreement to acquire the Breathe Right brand for $1.045 billion, expected to become its largest brand and enhance the company's international presence in the health care market, likely boosting future revenue.
- Shareholder Activism Catalyst: Ingles Markets is facing a challenge from investment firm Summer Road LLC, which could act as a catalyst for unlocking value, although investors should proceed cautiously and consider gradual accumulation to mitigate potential risks.
See More
Health Care Stocks Decline Late Friday
- Overall Decline: Late Friday, the NYSE Health Care Index experienced a downturn, indicating increasing market concerns about the healthcare sector, which may negatively impact investor confidence.
- Market Reaction: The decline in healthcare stocks may be linked to overall economic uncertainty, as investors anticipate potential policy changes that could lead to capital outflows from the sector, thereby affecting stock performance.
- Industry Impact: The weak performance of the healthcare sector could hinder related companies' financing capabilities and market valuations, especially under the current economic conditions where operational pressures are heightened.
- Investor Strategy Adjustment: As healthcare stocks decline, investors may reassess their portfolios, considering reallocating funds to other sectors with greater growth potential to mitigate risks associated with market volatility.
See More
Prestige Consumer to Acquire Breathe Right Brand for $1.045 Billion
- Acquisition Overview: Prestige Consumer Healthcare is set to acquire the Breathe Right brand and other OTC health products from Foundation Consumer Brands for $1.045 billion in cash, with the deal expected to close in the first half of fiscal 2027, indicating a proactive strategy in expanding its product portfolio.
- Financial Highlights: The acquired portfolio includes Dimetapp and Anbesol, generating $200 million in annual revenue and $95 million in EBITDA, suggesting that this acquisition will significantly enhance Prestige's financial foundation and competitive position in the market.
- Financing Strategy: Prestige plans to finance the acquisition using cash on hand and a new term loan, demonstrating flexibility in capital management and confidence in future growth, although it may impact short-term liquidity.
- Market Reaction: Following the acquisition announcement, Prestige Consumer Healthcare's stock rose 1.6% in premarket trading, reflecting investor optimism about the deal and its potential to drive further growth in the OTC market.
See More
